On 1 July 2025, Alvotech and Advanz Pharma announced that the companies have entered into a European supply and commercialisation agreement for AVT10, Alvotech’s biosimilar to UCB’s Cimzia® (certolizumab pegol).
The announcement follows Alvotech’s acquisition of Xbrane’s biosimilar certolizumab pegol in June 2025, together with Xbrane’s Swedish R&D operations.
Alvotech and Advanz entered into partnership agreements in February 2023, May 2023 and June 2024 for commercialisation of certain biosimilars in Europe and certain other countries, including AVT23 (biosimilar to Novartis’ Xolair® (omalizumab)), AVT05 (biosimilar to Janssen’s Simponi® and Simponi Aria® (golimumab)), AVT16 (biosimilar to Takeda’s Entyvio® (vedolizumab)), AVT06 and AVT29 (biosimilars to Regeneron’s Eylea® (aflibercept) in low (2mg) and high (8mg) doses, respectively), and biosimilars to Sanofi/Regeneron’s Dupixent® (dupilumab), Eli Lily’s Taltz® (ixekizumab) and J&J/Janssen’s Tremfya® (guselkumab). In May 2025, the companies expanded their partnership to include biosimilars to Novartis’ Ilaris® (canakinumab) and Kesimpta® (ofatumumab).